Introduction
The BCR/ABL fusion gene, generated by a reciprocal t(9;22) chromosomal translocation causing the Philadelphia (Ph) chromosome, is the molecular signature of chronic myeloid leukemia (CML) and is also observed in 30-40% of acute lymphoblastic leukemia (ALL) (Goldman and Melo, 2003; Wong and Witte, 2004) . The BCR/ ABL fusion protein is a tyrosine kinase that is constitutively activated and confers survival and proliferation advantages to hematopoietic cells, thus contributing to leukemogenesis. BCR/ABL activates various intracellular signaling pathways, such as those involving Ras, Rap1, B-Raf, Raf-1, Erk, phosphatidylinositol 3-kinase, STAT5 and NFkB, which normally play roles in regulation of hematopoiesis by hematopoietic cytokines and other extracellular stimuli (Goldman and Melo, 2003; Wong and Witte, 2004; Jin et al., 2006) . Imatinib (STI-571), a tyrosine kinase inhibitor that blocks the catalytic activity of BCR/ABL, has demonstrated the striking efficacy in treatment of CML or Ph chromosome-positive ALL (Goldman and Melo, 2003; Wong and Witte, 2004; Deininger et al., 2005; O'Hare et al., 2006) . Imatinib inhibits proliferation and induces apoptosis of BCR/ABL-expressing leukemic cells in vitro. However, the resistance to imatinib may develop in significant portions of patients under treatment, especially in those with CML in advanced stages or with ALL, mostly due to the emergence of mutations in the BCR/ABL kinase domain that may inhibit binding of imatinib to the kinase domain, including the most frequent E255K and T315I mutations (Goldman and Melo, 2003; Wong and Witte, 2004; Deininger et al., 2005; O'Hare et al., 2006) . We previously showed that the BCR/ABL kinase domain with either E255K or T315I exhibited not only the resistance to imatinib but also the increase in activity to induce autophosphorylation as well as tyrosine phosphorylation of various cellular proteins, including STAT5, when expressed in COS7 cells (Yamamoto et al., 2004) . Thus, it is possible that these mutations may confer the growth advantage on leukemic cells to expand in the absence of selective pressure from imatinib treatment. Consistent with this, leukemic clones harboring some of these mutations preexist at detectable levels before imatinib therapy in some patients with BCR/ABL-expressing leukemias (Roche-Lestienne et al., 2002; Shah et al., 2002; Hofmann et al., 2003; Kreuzer et al., 2003; RocheLestienne et al., 2003; Willis et al., 2005) . It should be also noted that BCR/ABL transcripts remain detectable by reverse transcriptase-polymerase chain reaction (RT-PCR) in the majority of patients with CML in the chronic phase responding to initial treatment with imatinib (Hughes et al., 2003) . The molecular persistence has been traced in part to a population of leukemic stem cells, which may represent a potential pool from which the resistance emerges (Deininger et al., 2005; O'Hare et al., 2006) . Although two investigational ABL kinase inhibitors, dasatinib and AMN107 (Shah et al., 2004; Weisberg et al., 2005) , have shown some efficacy in phase I clinical trials for the treatment of imatinibresistant CML and Ph-positive ALL, it has remained to be known if more than complete cytogenetic response could be obtained with these new agents (Shah, 2005) . Furthermore, the T315I BCR/ABL mutant remains resistant to these agents. Therefore, studies aiming to develop new therapies to prevent or counteract the imatinib resistance and to eradicate leukemic stem cells are needed.
Protein kinase C-d (PKCd) is a ubiquitously expressed isoform of the novel PKC subfamily and has been implicated in regulation of apoptosis in various cellular systems (Brodie and Blumberg, 2003) . It has been reported that PKCd can be either proapoptotic or antiapoptotic, depending on the specific cellular system and the specific ligand. Many of these studies have used rottlerin (Gschwendt et al., 1994) as a specific inhibitor of PKCd, in conjunction with other methods, as evidence for its involvement in regulation of apoptosis of various types of cells (Brodie and Blumberg, 2003) . For instance, rottlerin at high concentrations (5 or 10 mM) has been shown to induce apoptosis in various leukemic cell lines as well as primary multiple myeloma or chronic lymphocytic leukemia cells, thus implicating PKCd in regulation of survival of these cells (Ringshausen et al., 2002; Ni et al., 2003; Liao et al., 2005) . Although rottlerin was originally described as a specific inhibitor of PKCd and calmodulin kinase III (Gschwendt et al., 1994) , the specificity has been questioned by Davies et al. (2000) who failed to observe a direct effect of rottlerin on in vitro PKCd kinase activity. Soltoff (2001) further revealed that rottlerin acts as a mitochondrial uncoupler. Thus, effects of rottlerin on apoptosis and other cellular processes need to be interpreted cautiously.
In the present study, we analysed the effect of rottlerin on imatinib-induced apoptosis of BCR/ABL-expressing cells in an effort to explore the possible involvement of PKCd. Rottlerin did not significantly affect the PKCd and BCR/ABL activities in these cells. However, rottlerin as well as two other mitochondrial uncouplers examined induced a rapid and transient decline in mitochondrial membrane potential (Dc m ) and synergistically enhanced imatinib-induced apoptosis. The synergistic effect of rottlerin on imatinib-induced apoptosis was also observed in cells expressing the E255K BCR/ ABL mutant showing imatinib resistance as well as enhanced kinase activity.
Results
Rottlerin synergistically enhances imatinib-induced apoptosis of BCR/ABL-expressing cells To try to investigate a possible involvement of PKCd in regulation of apoptosis in BCR/ABL expressing cells, we treated CML-derived K562 cells with rottlerin, a reagent widely used as a PKCd-specific inhibitor, and examined apoptosis of these cells by the Annexin Vbinding assay using flow cytometer. As shown in Figure  1a and b, treatment of K562 cells with imatinib at 1 or 2 mM only slightly increased apoptotic cells. Treatment for 24 h with rottlerin at 2 or 5 mM alone did not induce any significant apoptosis of K562 cells. However, when cells were treated with both rottlerin and imatinib at these concentrations, apoptosis was drastically induced (Figure 1a and b). The synergistic enhancement of imatinib-induced apoptosis by rottlerin was also demonstrated by the Trypan blue dye exclusion assay as shown in Figure 1c . In contrast, rottlerin did not show any enhancing effect on etoposide-induced apoptosis of K562 cells and mitigated bortezomib-induced apoptosis ( Figure 1c) . Similarly, apoptosis of Ton.B210 cells, a murine hematopoietic cell line that inducibly expresses BCR/ABL in the presence of doxycycline (DOX), was induced synergistically by treatment with rottlerin at 2 mM and imatinib at 1 mM, concentrations at which these inhibitors on their own only modestly induced apoptosis of Ton.B210 cells (data not shown).
PKCd is not involved in synergistic enhancement of imatinib-induced apoptosis by rottlerin To examine the possible involvement of PKCd in synergistic enhancement of imatinib-induced apoptosis by the putative PKCd inhibitor rottlerin, we directly examined the effect of rottlerin on kinase activity of PKCd by in vitro kinase assays using Histone H1 as substrate. Preliminary experiments revealed that the PKCd activity in K562 or Ton.B210 cells was very low and only faintly detectable (data not shown). Thus, we transiently expressed PKCd in COS7 cells and examined the effect of rottlerin treatment. As shown in Figure 2a , when transiently overexpressed in COS7 cells, PKCd was phosphorylated on Thr505 and showed a high level of kinase activity in in vitro kinase assay. However, treatment of COS7 transfectants with rottlerin at a concentration as high as 25 mM did not affect the kinase activity of PKCd (Figure 2a) . Furthermore, when added directly to the in vitro kinase reaction mixture, rottlerin at 25 mM also failed to show any inhibitory effect, whereas Go6850, a broad-spectrum PKC inhibitor, at 10 mM completely abolished the kinase activity of PKCd (Figure 2b ). These results are in agreement with previous reports that rottlerin did not inhibit the PKCd kinase activity in cells or in in vitro kinase assays (Davies et al., 2000; Soltoff, 2001 ) and suggest that rottlerin enhanced imatinib-induced apoptosis through a mechanism that is independent of PKCd.
To confirm this, we next examined Ton.B210 cells that were depleted of PKCd by long-term treatment with 12-O-tetradecanoylphorbol-13-acetate (TPA). Figure 2c shows that treatment of Ton.B210 cells with TPA for 8 h depleted PKCd and that further treatment of control cells with rottlerin in the presence or absence of imatinib did not affect the expression level of PKCd. Nevertheless, the synergistic effect of rottlerin on imatinibinduced apoptosis was observed in PKCd-depleted cells (Figure 2f and g) in a similar way with that in control cells (Figure 2d and e). These results thus confirm that PKCd was not involved in synergistic enhancement of imatinib-induced apoptosis by rottlerin.
The synergistic enhancement of imatinib-induced apoptosis of BCR/ABL by rottlerin is not through inhibition of BCR/ABL We next examined whether rottlerin may inhibit the kinase activity of BCR/ABL. As shown in Figure 3 , imatinib at 1 mM drastically inhibited both autophosphorylation of BCR/ABL and activation-specific tyrosine phosphorylation of STAT5, a well-established downstream target of BCR/ABL, as early as 3 h after treatment of K562 or Ton.B210 cells expressing BCR/ ABL. In contrast, rottlerin did not significantly affect tyrosine phosphorylation of these molecules during the observation periods up to 6 h. Neither rottlerin nor imatinib showed any effect on expression level of BCR/ ABL or STAT5. Thus, rottlerin affected neither kinase activity nor expression level of BCR/ABL in these cells. Taken together, these results indicate that rottlerin synergistically enhanced imatinib-induced apoptosis through a mechanism not involving direct inhibition of BCR/ABL or PKCd.
Synergistic enhancement of imatinib-induced apoptosis by mitochondrial uncouplers Soltoff (2001) previously demonstrated that rottlerin directly uncouples mitochondrial respiration from oxidative phosphorylation, because rottlerin treatment of cells increased the rate of oxygen consumption and at the same time reduced the cellular adenosine 5 0 triphosphate (ATP) level. To explore the possibility that rottlerin may enhance imatinib-induced apoptosis through this mechanism, we next examined the effect of carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP), a well-established mitochondrial uncoupler (Soltoff, 2001) . As shown in Figure 4a and b, a minimally toxic concentration of FCCP significantly enhanced imatinib-induced apoptosis of K562 cells, in a Rottlerin enhances imatinib-induced apoptosis T Kurosu et al Figure 2 Synergistic enhancement of imatinib-induced apoptosis by rottlerin is not through inhibition of PKCd. (a) COS7 cells were transfected with 1 mg of an empty vector or expression vector for PKCd, as indicated. Two days after transfection, cells were treated with or without 25 mM rottlerin for 1 h, as indicated, and harvested. Cell lysates were subjected to Western blot analysis with anti-PKCd (PKCd) and antiphospho-Thr505-PKCd (p-PKCd) as well as to the in vitro kinase assay for PKCd (IVK), as indicated. (b) COS7 cells were transfected with 1 mg of an empty vector or expression vector for PKCd, as indicated. Two days after transfection, cells were harvested for the in vitro PKCd kinase assay (IVK). The immunoprecipitates were reacted in vitro in the absence (Control) or presence of 25 mM rottlerin or 10 mM Go6850, as indicated. (c) Ton.B210 cells were cultured for 8 h in the presence or absence of 100 ng/ml TPA, as indicated, and a portion of cells was harvested. Cells were further cultured for 24 h in the presence or absence of 1 mM imatinib or 1 mM rottlerin, as indicated, and harvested. Cell lysates were subjected to Western blot analysis with anti-PKCd. (d, e, f, g) Ton.B210 cells were cultured in the absence of 100 ng/ml TPA in (d-e) or in its presence in (f-g) for 8 h. Cells were further cultured for 24 h in the presence or absence of 1 mM imatinib and 1 mM rottlerin, as indicated. Cells were stained with Annexin V-FITC as well as PI and analysed by flow cytometry (d, f). The percentages of cells staining positive for Annexin V (e, g). similar way with rottlerin ( Figure 1 ). As a mitochondrial uncoupler, rottlerin has been reported to reduce Dc m rapidly (Tillman et al., 2003) . We thus examined the effects of rottlerin and FCCP on Dc m of K562 cells and found that they similarly induced a rapid decline in Dc m as early as 15 min after treatment ( Figure 4e ). Dc m was most significantly reduced between 1 and 4 h after treatment with these reagents and gradually recovered thereafter to reach a near control level at 24 h.
We next examined the effect of a more clinically relevant mitochondria uncoupler, dinitrophenol (DNP), which had previously been widely used as an antiobesity drug (Harper et al., 2001) . As shown in Figure 4c and d, a minimally toxic concentration of DNP synergistically enhanced imatinib-induced apoptosis of K562 cells, in a similar way with rottlerin or FCCP. DNP also induced a rapid and significant decline in Dc m as early as 15 min after treatment (Figure 4f ). However, the decline in Dc m induced by DNP was observed only transiently and was much less than that induced by rottlerin or FCCP, thus suggesting that it may not be directly involved in enhancement of imatinib-induced apoptosis.
To examine more closely the significance of reduction in Dc m in enhancement of imatinib-induced apoptosis, we treated K562 cells with imatinib in the presence or absence of mitochondrial uncouplers and measured Dc m . As shown in Figure 4g , Dc m was significantly or only moderately reduced by treatment for 2 h with rottlerin or DNP, respectively. However, cotreatment with imatinib did not show any significant effect on reduction in Dc m by these mitochondrial uncouplers. Unexpectedly, imatinib induced a near twofold increase in Dc m after 24 h treatment in repeated experiments ( Figure 4g and data not shown). As expected, treatment for 24 h with rottlerin or DNP moderately decreased or increased the Dc m of K562 cells. Apparently, cotreatment with imatinib for 24 h did not show any significant effect on changes in Dc m induced by these mitochondrial uncouplers. However, close observation of Dc m levels in these cells revealed that Dc m was significantly increased, most likely due to imatinib, whereas a portion of cells showed a remarkable reduction in Dc m , which is most likely because these cells were already undergoing apoptosis ( Figure 4h ). Thus, imatinib did not aggravate the decline in Dc m induced by mitochondrial uncouplers but rather counteracted their effect. Together, these data suggest that the reduction in Dc m per se may not be directly involved in induction of apoptosis, although the mitochondrial uncoupling effect of rottlerin may play a critical role in synergistic enhancement of imatinibinduced apoptosis of BCR/ABL-expressing cells.
Involvement of MMP leading to cytochrome c release and activation of caspases in synergistic induction of apoptosis To explore the mechanisms by which mitochondrial uncouplers synergistically enhance imatinib-induced apoptosis of BCR/ABL-expressing cells, we examined the possible involvement of reactive oxygen species (ROS), which are produced mostly in mitochondria and are well-established regulators of apoptosis (Temple et al., 2005) . Thus, we next analysed the effects of mitochondrial uncouplers and imatinib on levels of ROS in K562 cells using dihydroethidium (HE), a redox sensitive fluorescence probe for superoxide (Rothe and Valet, 1990) . As shown in Figure 5a , rottlerin as well as FCCP drastically increased the ROS levels, which was observed as early as 2 h after treatment and was sustained for at least 12 h. However, the increase in ROS levels induced by mitochondrial uncouplers was not enhanced by cotreatment with 1 mM imatinib and, thus, may not be directly involved in synergistic induction of apoptosis in these cells.
We next examined the possible effect of mitochondrial uncouplers on mitochondria membrane permeabilization (MMP), which also plays a pivotal role in induction of apoptosis (Brenner and Grimm, 2006) . Cells were labeled with calcein-AM, which is converted to hydrophilic calcein within cells and trapped within subcellular compartments (Petronilli et al., 1999; Poncet et al., 2003; Brenner and Grimm, 2006) . Cells were also loaded with CoCl 2 , which quenches the fluoroprobe calcein in the cytosol but cannot diffuse into mitochondria owing to the impermeability of its membrane. When mitochondrial membrane permeability transition is induced, calcein is released from mitochondria and becomes quenched by CoCl 2 in the cytosol, resulting in a decreased fluorescence (Petronilli et al., 1999; Poncet et al., 2003; Brenner and Grimm, 2006) . As shown in Figure 5b , treatment of K562 cells with rottlerin or DNP for 4 h did not have any significant effect on the level of mitochondrial calcein fluorescence, which was in contrast to the rapid decline in Dc m . When treated with these mitochondrial uncouplers for 12 or 16 h, a small proportion of cells showed a decrease in the fluorescence level indicating the occurrence of MMP (Figure 5b and c). On the other hand, treatment with imatinib alone for as long as 16 h had at most a minor effect on MMP. However, imatinib drastically enhanced MMP that was induced by treatment for 12 or 16 h with the mitochondrial uncouplers. Thus, the mitochondrial uncouplers gradually induced MMP, which was in contrast to the rapid and transient decline in Dc m and was synergistically enhanced by cotreatment with imatinib.
MMP plays a crucial role in induction of apoptosis by allowing the release of aoptogenic factors including Figure 3 Rottlerin does not inhibit the BCR/ABL kinase activity. K562 (a) or Ton.B210 (b) cells were cultured for indicated times in the presence or absence of 1 mM imatinib and 1 mM rottlerin, as indicated, and harvested. Cell lysates were subjected to Western blot analysis with antiphosphotyrosine (PY) followed by sequential reprobing with antibodies against Abl, phospho-STAT5 (p-STAT5), and STAT5, as indicated.
Rottlerin enhances imatinib-induced apoptosis T Kurosu et al cytochrome c, SMAC and AIF into the cytoplasm (Brenner and Grimm, 2006) . Cytochrome c forms a complex with Apaf-1 and caspase-9 known as the apoptosome; this holoenzyme then cleaves and activates caspase-3, resulting in widespread proteolysis and cell death. To explore the possibility that MMP synergistically induced by mitochondrial uncouplers and imatinib is involved in induction of apoptosis, we next examined the cytoplasmic release of cytochrome c as well as activation of caspase-9 and caspase-3 in K562 cells. As d) . (e, f) K562 cells were cultured for indicated times with 2 mM rottlerin, 10 mM FCCP, or 0.5 mM DNP, as indicated, and subjected to the flow cytometric analysis for Dc m as described in 'Materials and methods'. (g) K562 cells were cultured for indicated times with 2 mM rottlerin or 0.5 mM DNP in the presence or absence of 1 mM imatinib, as indicated, and subjected to the flow cytometric analysis for Dc m . Each data points represent relative Dc m compared with the pretreatment control level. (h) K562 cells were cultured for 24 h with 2 mM rottlerin or 0.5 mM DNP in the presence or absence of 1 mM imatinib, as indicated, or left untreated as control and subjected to the flow cytometric analysis for Dc m .
Rottlerin enhances imatinib-induced apoptosis
T Kurosu et al shown in Figure 5d , cytochrome c was not detectable in the cytoplasmic fraction of K562 cells treated with imatinib or rottlerin alone for as long as 24 h. However, the release of cytochrome c into the cytoplasm was observed in K562 cells treated with both imatinib and rottlerin. Furthermore, the activated forms of caspase-9
and -3 as well as the cleaved form of PARP, a wellestablished substrate for caspase-3, were observed in K562 cells only when treated with both imatinib and rottlerin (Figure 5e ). By the methods we employed, the release of cytochrome c from mitochondria was observed as early as 12 h after treatment with imatinib Rottlerin enhances imatinib-induced apoptosis T Kurosu et al and rottlerin, while the activation of caspases was observed after 16 h (data not shown). Finally, the pancaspase inhibitor z-VAD-fmk significantly inhibited apoptosis induced synergistically with imatinib and rottlerin (Figure 5f and g), thus indicating that it is induced at least partly through activation of caspases. Together, these results strongly implicate MMP, which was synergistically induced by rottlerin and imatinib leading to the release of cytochrome c and subsequent activation of caspases-3 and -9, in synergistic induction of apoptosis of BCR/ABL-expressing cells.
Effects of rottlerin and imatinib on primary leukemic cells expressing BCR/ABL
We next treated BCR/ABL-expressing primary leukemic cells ex vivo with rottlerin and imatinib to examine their cytotoxicities. As shown in Figure 6a , 1 mM of imatinib or rottlerin reduced by only about 10% the viable cell number of leukemic cells from a patient with CML in blastic crisis who had previously been treated with imatinib, whereas treatment with both imatinib and rottlerin reduced it by about 30%. Similarly, the viable cell number of leukemic cells expressing p190
BCR/ABL from a patient with Ph-positive ALL was reduced by less than 10% when treated with 0.5 mM imatinib or 1 mM rottlerin alone, while it was reduced by more than 40% when treated with both imatinib and rottlerin at these concentrations ( Figure 5b ). Rottlerin also significantly enhanced the effect of imatinib on p190
BCR/ABL -expressing leukemic blasts from a patient with Ph-positive biphenotypic acute leukemia (Figure 6c ). These results show that rottlerin exerted a synergistic, or at least additive, effect ex vivo on BCR/ABL-expressing primary leukemic blasts from these three patients we could examine and further indicate that rottlerin enhanced imatinib-induced apoptosis of cells expressing not only p210 BCR/ABL but also p190 BCR/ABL .
Rottlerin confers imatinib sensitivity on cells expressing BCR/ABL with the imatinib resistance E255K mutation
To examine whether rottlerin synergistically enhances the effect of imatinib on cells expressing imatinib-resistant BCR/ABL mutants, we first examined Ton.B210/E255K cells, a clone expressing one of the most prevalent BCR/ ABL kinase-domain mutants associated with imatinib resistance. As judged from levels of tyrosine phosphorylation of BCR/ABL and STAT5, BCR/ABL with the E255K mutation exhibited a kinase activity higher than that of BCR/ABL without mutation when expressed at comparable levels ( Figure 7a ). This is in agreement with our previous observation that the BCR/ABL kinase domain with E255K showed higher in vitro and in vivo kinase activities (Yamamoto et al., 2004) , although the enhancement of kinase activity was not as remarkable as that observed when only the kinase domain was expressed in COS cells. As compared with BCR/ABL without mutation, BCR/ABL with E255K was inhibited much less significantly by 1 or 2 mM imatinib as expected (Figure 7a ). We then examined the effects of rottlerin and imatinib on Ton.B210/E255K. As shown in Figure 7b , treatment with 1 mM imatinib for 3 or 6 h only slightly inhibited autophosphorylation of BCR/ABL and activationspecific tyrosine phosphorylation of STAT5 in Ton.B210/E255K cells, which is in contrast to the drastic inhibition observed in Ton.B210 cells (Figure 3b ). Rottlerin neither showed any significant effect on tyrosine phosphorylation of these molecules alone nor enhanced the inhibitory effect of imatinib. As shown in Figure 7c and d, treatment of Ton.B210/E255K cells for 24 h with imatinib at 1 or 2 mM did not show any significant effect on apoptosis. Treatment for 24 h with 1 mM rottlerin also failed to induce apoptosis in Ton.B210/E255K. However, when these cells were treated with both rottlerin and imatinib at these concentrations, apoptosis was significantly induced (Figure 7c and d) . These results indicate that rottlerin, without affecting the kinase activity of the BCR/ABL mutant, remarkably sensitized cells expressing the imatinib-resistant E255K mutant to imatinib.
We also examined Ton.B210/T315I cells expressing BCR/ABL with the T315I mutation. Similarly with BCR/ABL with the E255K mutation, the T315I mutant also exhibited a kinase activity higher than that of BCR/ ABL without mutation when expressed at comparable levels (Figure 7e ), which agrees with our previous report (Yamamoto et al., 2004) . Figure 7e also shows that the T315I mutant was much more resistant to imatinib as compared with the E255K mutant, which also agrees with previous reports and is most likely because the T315I mutation directly blocks binding of imatinib to the ATP-binding pocket (Goldman and Melo, 2003; Wong and Witte, 2004; Deininger et al., 2005 ; O'Hare et al., 2006). In contrast with the result with Ton.B210/E255K, rottlerin failed to sensitize Ton.B210/T315I cells to imatinib (negative data not shown).
Discussion
The present study has demonstrated that rottlerin, a putative PKCd inhibitor, synergistically enhanced imatinibinduced apoptosis of BCR/ABL-expressing cells, K562 and Ton.B210. However, the synergistic effect of rottlerin was independent of PKCd, because rottlerin failed to inhibit the PKCd kinase activity and showed the similar effect in cells depleted of PKCd. Rottlerin also failed to inhibit BCR/ABL, as judged by its ability to phosphorylate itself or its substrate, STAT5. On the other hand, rottlerin rapidly decreased Dc m , an effect characteristic of mitochondrial uncouplers. Furthermore, two other mitochondrial uncouplers tested, FCCP and DNP, rapidly reduced Dc m and synergistically enhanced imatinib-induced apoptosis of BCR/ABLexpressing cells in a similar way with rottlerin. However, the decline in Dc m showed a poor correlation with apoptosis in cells cotreated with imatinib, thus suggesting that the decline in Dc m per se may not be directly responsible for the synergistic effect with imatinib. On the other hand, MMP was induced synergistically by treatment with imatinib and mitochondrial uncouplers and correlated with induction of apoptosis. Furthermore, the release of cytochrome c into the cytoplasm and activation of caspases-3 and -9, which are events downstream of MMP, were observed in K562 cells treated with imatinib and rottlerin, and the pan-caspase inhibitor z-VAD-fmk at least partly inhibited the synergistic induction of apoptosis. Rottlerin significantly enhanced cytotoxicity of imatinib on BCR/ ABL-expressing leukemic blasts from patients with CML in blast crisis as well as with Ph-positive ALL or biphenotypic acute leukemia. Rottlerin also sensitized cells expressing BCR/ABL with the E255K mutation, which enhances the kinase activity and makes it resistant to imatinib, although rottlerin failed to sensitize Ton.B210/T315I cells expressing the imatinib-insensitive mutant to imatinib. These results demonstrate that mitochondrial uncouplers, such as rottlerin, synergistically enhance the effect of imatinib on leukemic cells expressing BCR/ABL, including the E255K mutant prevalently observed in cases with imatinib resistance, and provide evidence for their potential value in development of new therapeutic strategies for treatment of BCR/ABL-positive leukemias including those resistant to imatinib.
Although rottlerin has been widely used as an inhibitor for PKCd, we failed to observe any inhibitory effect of rottlerin on PKCd in cells or in in vitro kinase assays. This is in accordance with a previous report that rottlerin inhibited several kinases but in fact not PKCd in vitro (Davies et al., 2000) . Moreover, Soltoff (2001) demonstrated that rottlerin actually increased the PKCd activity in in vitro kinase assays in the absence of lipid cofactors, which agrees with our observation. Soltoff (2001) further showed for the first time that rottlerin directly uncouples mitochondrial respiration from oxidative phosphorylation. Rottlerin thereby significantly reduced the cellular ATP levels in primary or nontransformed cells, thus indirectly reducing activities of various kinases including PKCd in these cells (Soltoff, 2001) . However, rottlerin failed to inhibit PKCd and other kinases through this mechanism in transformed cells in culture, which rely on glycolysis rather than oxidative phosphorylation for energy-dependent processes. In agreement with this, rottlerin did not reduce the ATP content of K562 cells (our unpublished observation). Thus, rottlerin failed to inhibit the BCR/ ABL activity in K562 or Ton.B210 cells after treatment for 6 h in the present study (Figure 3) . Moreover, the synergistic effect of rottlerin and imatinib was observed also in cells depleted of PKCd after a long-term treatment with TPA (Figure 2) . These results indicate that the synergistic enhancement of imatinib-induced apoptosis by rottlerin and other mitochondrial uncouplers is mediated neither through direct inhibition of PKCd nor indirect inhibition of PKCd and other kinases by ATP depletion.
Previously, Tillman et al. (2003) have reported that rottlerin sensitized colon cancer cells to tumour-necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in a PKCd-independent manner. The authors suggested that the sensitization may be mediated by the decrease in Dc m , which is caused by mitochondrial uncoupling and may impair mitochondrial membrane function leading to the release into the cytosol of mitochondrial proteins that are involved in apoptotic processes. In the present study, however, the decline in Dc m induced by rottlerin or by the other mitochondrial uncouplers was transient and was mostly recovered after 24 h, when apoptosis was examined (Figure 4) . Furthermore, treatment of cells with imatinib alone unexpectedly but consistently increased Dc m . Although we observed a population of cells that showed drastically decreased levels of Dc m after treatment for 24 h with rottlerin and imatinib, these cells most likely represented cells already undergoing apoptosis. These results are incongruous with the idea that the decrease in Dc m is directly responsible for the synergistic induction of apoptosis. On the other hand, MMP was induced more gradually by mitochondrial uncouplers, synergistically enhanced by imatinib, and followed by the release of cytochrome c into the cytoplasm, resulting in activation of caspases-3 and -9 (Figure 5b-e) .
It was also demonstrated that the pan-caspase inhibitor z-VAD-fmk at least partly inhibited the synergistic induction of apoptosis (Figure 5f and g ). These data suggest that mitochondrial uncoupling may impair mitochondrial membrane function leading to MMP, which is drastically enhanced by cotreatment with imatinib, thus leading to synergistic induction of apoptosis mediated by caspase activation. It should be noted, however, that the impairment of mitochondrial function induced by mitochondrial uncoupling was not necessarily enhanced by apoptosis-inducing signals in general. This is because rottlerin failed to enhance etoposide-induced apoptosis of K562 cells and endowed these cells with resistance to bortezomib, which agrees with a previous report by Durrant et al. (2004) (Figure 1c ). Future studies are thus need to address the mechanism by which imatinib specifically enhances the mitochondrial impairment induced by mitochondrial uncoupling.
The synergistic enhancement of imatinib-induced apoptosis of BCR/ABL-expressing cells by mitochondrial uncouplers at minimally toxic concentrations may offer a novel means by which to surmount the imatinib resistance or to eradicate BCR/ABL-expressing leukemic cells to cure the disease. It should be noted that the combination of imatinib and mitochondrial uncouplers showed only a minimally toxic effect on Ton.BaF cells cultured in the presence of interleukin (IL)-3 (data not shown). Thus, the synergistic effect was specific for hematopoietic cells dependent on BCR/ABL and should not be observed in cytokine-dependent normal hematopoietic cells. Also noteworthy in this regard is the fact that the mitochondrial uncoupler DNP was widely used to treat obesity in 1930s (Harper et al., 2001) . However, because of reports of side effects, such as cataracts, and some deaths from accidental or deliberate overdose, DNP was officially chased off the market by the US Food and Drug Administration in 1938. As the steep dose dependence of its effects as well as the widespread use with prescription by inexperienced physicians prevented the safe clinical use of DNP (Harper et al., 2001) , mitochondrial uncouplers with better pharmacological safety profiles need to be developed for a possible future therapeutic trial for BCR/ABL-expressing leukemias as well as for obesity. It is also noteworthy that there exist endogenous mitochondrial uncoupling proteins (UCPs), including UCP-1, UCP-2 and UCP-3, which can be activated by free radicals or free fatty acids and are implicated in protection against neuronal damages (Echtay et al., 2002; Mattiasson et al., 2003; Krauss et al., 2005) . For instance, in similar ways with DNP administration, UCP-2 has been shown to cause mild mitochondrial uncoupling when overexpressed in experimental animals by genetical engineering or by feeding ketogenic diet and to reduce neuronal death induced by experimental damage. Thus, possible synergistic effects on imatinib-induced apoptosis of BCR/ ABL-expressing cells need to be evaluated for activation or overexpression of these endogenous uncoupling proteins in future studies. It is also important to evaluate the possible synergism between mitochondrial uncouplers and the second-generation BCR/ABL inhibitors dasatinib and AMN107 (Shah et al., 2004; Weisberg et al., 2005) . Future studies also need to examine whether mitochondrial uncouplers synergistically enhance the effect of imatinib in leukemic stem cells expressing BCR/ABL to explore their therapeutic potential for significantly enhancing the efficacy of imatinib to cure the disease.
Materials and methods

Cells and reagents
A human CML cell line, K562, was maintained in Rosewell's Park Memorial Institute (RPMI) 1640 medium supplemented with 10% fetal calf serum (FCS). A clone of murine IL-3-dependent BaF3 cells transfected with a BCR/ABL cDNA under the control of a tetracycline-inducible promoter, Ton.B210, and the parental control clone, Ton.BaF, were kindly provided by Dr George Q Daley (Klucher et al., 1998) . Ton.BaF or Ton.B210 cells were cultured in 10% FCScontaining RPMI 1640 medium supplemented, respectively, with 10% Wehi3B conditioned medium as the source of IL-3 or with 1 mg/ml DOX, which induces the expression of BCR/ABL. Leukemic blasts were isolated from a patient with CML myeloid crisis, Ph-positive ALL, or Ph-positive biphenotypic acute leukemia. Informed consent was provided according to the Declaration of Helsinki, and the study was approved by the ethical committee of Tokyo Medical and Dental University. Mononuclear cells were isolated by centrifugation through Ficoll-Hypaque, washed in RPMI 1640 medium supplemented with 10% FCS, and cryopreserved. The percentages of blasts in the samples determined morphologically were more than 90%.
The ABL kinase inhibitor imatinib was kindly provided by Novartis (Basel, Switzerland). Recombinant murine IL-3 was purchased from PeproTech (Rocky Hill, NJ, USA). Rottlerin, Go6850 and z-VAD-fmk were obtained from Calbiochem (San Diego, CA, USA), and bortezomib was from Millennium Pharmaceuticals (Cambridge, MA, USA). DOX, etoposide, Histone H1, FCCP, DNP and CoCl 2 were from Sigma (St Louis, MO, USA). HE was purchased from Molecular Probes (Eugene, OR, USA). Calcein-AM was purchased from Wako Chemicals (Osaka, Japan). Antibodies against Abl (K-12), STAT5, PKCd, caspase-9 and a-tubulin were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). An antiphosphotyrosine monoclonal antibody (4G10) and anticytochrome c antibody were purchased from Upstate Biotechnology (Lake Placid, NY, USA) and BD Biosciences (San Diego, CA, USA), respectively. Phosphospecific antibodies against PKCd (Thr505) and STAT5 (Tyr694) and antibodies against Caspase-3 and PARP were from Cell Signaling (Beverly, MA, USA).
Establishment of BaF3 clones expressing BCR/ABL with E255K or T315I mutation An expression plasmid for BCR/ABL with E255K or T315I mutation (pTet-p210-E255K or pTet-p210-T315I) was constructed by subcloning the KpnI-AatII fragment coding for the mutated ABL kinase domain from pCMV-tag1-E255K or pCMV-tag1-T315I (Yamamoto et al., 2004) , respectively, into pTet-splice-p210. Transfection for stable expression was performed essentially as described previously (Miura et al., 1993) . In brief, Ton.BaF cells, a BaF3 cell line expressing the reverse tet-transactivator, were transfected with 15 mg of pTetp210-E255K or pTet-p210-T315I along with 1 mg of pMAM2-BSD (Funakoshi, Tokyo, Japan) by electroporation at 960 mF and 280 V, followed by selection in medium containing blasticidin-S (Funakoshi). Clones were isolated by limiting dilution and examined for the expression of BCR/ABL by immunoblotting. A clone inducibly expressing BCR/ABL with E255K or T315I mutation in the presence of DOX were designated as Ton.B210/E255K or Ton.B210/T315I, respectively. These clones were cultured in 10% FCS-containing RPMI 1640 medium supplemented with 20 ng/ml DOX, because they expressed mutant BCR/ABL at levels comparable with that in Ton.B210 cells cultured with 1000 ng/ml Dox.
Immunoprecipitation and immunoblotting
For immunoprecipitation experiments, cells were lysed in a lysis buffer containing 1% Triton X-100, 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM ethylenediamine-N,N,N 0 ,N 0 -tetraacetic acid (EDTA), 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride and 10 mg/ml each of aprotinin and leupeptin. Cell lysates were subjected to immunoprecipitation and immunoblotting essentially as described previously (Miura et al., 1993) . For immunoblot analysis of total cell lysates, samples were prepared by mixing an aliquot of cell lysates with an equal volume of 2 Â Laemmli's sample buffer and heating at 1001C. Samples were separated by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) and electrotransferred to Immobilon P membrane (Millipore, Bedford, MA, USA). The membranes were probed with a relevant antibody followed by detection using enhanced chemiluminescence Western blotting detection system (Amersham Pharmacia Biotech, Buckinghamshire, England). For reprobing of the membranes, the membranes were treated with stripping buffer composed of 100 mM 2-mercaptoethanol, 2% SDS and subsequently probed with a different antibody.
To detect cytochrome c release, mitochondria-free cytosol was prepared essentially as described previously (Yang et al., 1997) . In brief, cells were lysed in ice-cold Mito-buffer (20 mM 2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid, pH 7.5, 10 mM KCl, 1.5 mM MgCl 2 , 1 mM EGTA, 1 mM EDTA, 1 mM dithiothreitol (DTT), 250 mM sucrose, 0.1 mM phenylmethylsulphonyl fluoride, 10 mg/ml leupeptin and 10 mg/ml aprotinin) by homogenization using a Dounce homogenizer (40 strokes on ice). The homogenates were first spun at 800 g for 20 min to remove nuclei and cell debris, then spun at 16 000 g for 20 min at 41C twice to remove the residual mitochondria, and the supernatants were used for anticytochrome c Western blot analysis.
Analyses of cell viability, apoptosis and Dc m For analysis of cell viability of primary leukemic cells, cells were thawed and cultured for 1 day in RPMI 1640 medium with 10% FCS. Then, cells were washed, resuspended in RPMI 1640 with 10% FCS at 1 Â 10 5 /ml, and plated triplicate with indicated reagents. Cells were further cultured for 24 h, and cell viability was determined by the Trypan blue dye exclusion method.
Apoptosis and Dc m were analysed by flow cytometry as described previously (Kurosu et al., 2003) . In brief, cells were stained with Annexin V-FITC and propidium iodide (PI) using the TACS Annexin V Kit (Trevigen, Gaithersburg, MD, USA) and analysed using a Becton Dickinson FACSscan flow cytometer (Mountain View, CA, USA) for apoptosis. For analysis of Dc m , cells were stained with a lipophilic cation (5,5 0 ,6,6 0 ,tetrachloro-1,1 0 ,3,3 0 -tetraethylbenzimidazolyl carbocyanin iodide) using the DePsipher kit (Trevigen, Gaitherburg, MD, USA) and analysed by flow cytometry.
Analyses of ROS and MMP Intracellular ROS levels were measured fluorometrically using a fluorescent probe, HE, which is oxidized to the fluorescent intercalator ethidium by cellular oxidants, particularly superoxide radicals (Rothe and Valet, 1990) , as described previously (Kurosu et al., 2003) . In brief, 1 Â 10 6 cells were incubated with 2 mM HE for 30 min at 371C, resuspended in phosphatebuffered saline (PBS), and analysed by flow cytometry.
MMP was assessed by using calcein-AM and CoCl 2 , essentially as described previously (Poncet et al., 2003) . In brief, cells were preincubated for 15 min at 371C with 1 mM calcein-AM and 1 mM CoCl 2 in Hank's balanced salt solution. Cells were then replated in complete culture medium and treated with or without imatinib and mitochondrial uncouplers for indicated times and analysed by flow cytometry.
PKCd in vitro kinase assays Cells were lysed in a lysis buffer containing 1% Triton X-100, 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 10 mM NaF, 1 mM EDTA, 1 mM EGTA, 10 mM 2-mercaptoethanol, 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride and 10 mg/ ml each of aprotinin and leupeptin. PKCd was immunoprecipitated and incubated with ATP (20 mM with 10 mCi [g-32 P]ATP) and 10 mg Histone H1 at 301C for 15 min in a kinase reaction buffer containing 20 mM Tris-HCl (pH 7.5) and 10 mM MgCl 2 . The samples were resolved by SDS-PAGE and subjected to autoradiography.
For transient expression of PKCd in COS7 cells, cells were transfected with pMTH-PKC-d (Romanova et al., 1999) , kindly provided by Dr Larisa Y Romanova, as described previously (Chin et al., 1996) . Cells were harvested for the PKCd in vitro kinase assays 2 days after transfection. In some experiments, immunoprecipitates were exposed to indicated concentrations of rottlerin or Go6850 for 15 min at 301C before initiating the assay by adding ATP and Histone H1.
